Simponi Aria is now approved to to treat patients 2 years and older with active polyarticular juvenile Idiopathic arthritis (pJIA) and psoriatic arthritis (PsA).
FDA expanded the indication for the rheumatoid arthritis (RA) medication golimumab (Simponi Aria, Janssen) to treat patients 2 years and older with active polyarticular juvenile Idiopathic arthritis (pJIA) and psoriatic arthritis (PsA).
Simponi Aria is already approved Ito treat adults with moderately to severely active RA, active PsA, and active ankylosing spondylitis (AS).
Related: Another RA drug starts testing to treat COVID-19
“This latest FDA approval of Simponi Aria for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, MD, PhD, global head of Janssen Research & Development at Johnson & Johnson, in a press release.
“For far too long, children with pJIA or PsA have had limited treatment options,” said Seth D. Ginsberg, co-founder and president of the Global Healthy Living Foundation and CreakyJoints. “This approval represents an important step forward for these children and their families.”
Related: RA drug could help pharma maker stunt Humira losses
The approval was based on results from the GO-VIVA Phase 3 clinical trial, an open-label study in children with JIA with active polyarthritis. The children, ages 2 to 17 years old, had active arthritis in five or more joints despite receiving treatment with methotrexate for at least 2 months.
Trial results demonstrated that Simponi Aria was generally consistent with responses in adult patients with RA.
Simponi Aria is a fully human anti-TNF-alpha monoclonal antibody that targets both soluble and transmembrane bioactive forms of human TNFalpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation.
Read more: New RA biosimilar impact hinges on patent lawsuit
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More